High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina

Adamis, 2002, Is diabetic retinopathy an inflammatory disease?, Br. J. Ophthalmol., 86, 363, 10.1136/bjo.86.4.363

Andersson, 2000, High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes, J. Exp. Med., 192, 565, 10.1084/jem.192.4.565

Antonetti, 1998, Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group, Diabetes, 47, 1953, 10.2337/diabetes.47.12.1953

Barber, 2000, Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group, Invest. Ophthalmol. Vis. Sci., 41, 3561

Bazzoni, 2004, Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis, Physiol. Rev., 84, 869, 10.1152/physrev.00035.2003

Behzadian, 1998, Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-beta, Glia, 24, 216, 10.1002/(SICI)1098-1136(199810)24:2<216::AID-GLIA6>3.0.CO;2-1

El-Asrar, 2012, Role of inflammation in the pathogenesis of diabetic retinopathy, Middle East Afr. J. Ophthalmol., 19, 70, 10.4103/0974-9233.92118

El-Asrar, 2011, High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy, Mol. Vis., 17, 1829

El-Asrar, 2011, Expression of high-mobility groups box-1/receptor for advanced glycation end products/osteopontin/early growth response-1 pathway in proliferative vitreoretinal epiretinal membranes, Mol. Vis., 17, 508

Fiuza, 2003, Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells, Blood, 101, 2652, 10.1182/blood-2002-05-1300

Furuse, 1993, Occludin: a novel integral membrane protein localizing at tight junctions, J. Cell. Biol., 123, 1777, 10.1083/jcb.123.6.1777

Gong, 2012, Glycyrrhizin attenuates rat ischemic spinal cord injury by suppressing inflammatory cytokines and HMGB1, Acta Pharmacol. Sin., 33, 11, 10.1038/aps.2011.151

Hirase, 1997, Occludin as a possible determinant of tight junction permeability in endothelial cells, J. Cell. Sci., 110, 1603, 10.1242/jcs.110.14.1603

Ishida, 2003, VEGF164 is proinflammatory in the diabetic retina, Invest. Ophthalmol. Vis. Sci., 44, 2155, 10.1167/iovs.02-0807

Kaji, 2007, Inhibition of diabetic leukostasis and blood–retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products, Invest. Ophthalmol. Vis. Sci., 48, 858, 10.1167/iovs.06-0495

Kim, 2011, The role of high-mobility group box-1 protein in the development of diabetic nephropathy, Am. J. Nephrol., 33, 524, 10.1159/000327992

Kim, 2012, Glycyrrhizic acid affords robust neuroprotection in the postischemic brainvia anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion, Neurobiol. Dis., 46, 147, 10.1016/j.nbd.2011.12.056

Kokkola, 2002, High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis, Arthritis Rheum., 46, 2598, 10.1002/art.10540

Kowluru, 2003, Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants, Free Radic. Res., 37, 1169, 10.1080/10715760310001604189

Krady, 2005, Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy, Diabetes, 54, 1559, 10.2337/diabetes.54.5.1559

Lander, 1997, Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress, J. Biol. Chem., 272, 17810, 10.1074/jbc.272.28.17810

Lotze, 2005, High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal, Nat. Rev. Immunol., 5, 331, 10.1038/nri1594

Luan, 2010, HMGB1 activates nuclear factor-κB signaling by RAGE and increases the production of TNF-α in human umbilical vein endothelial cells, Immunobiology, 215, 956, 10.1016/j.imbio.2009.11.001

Mitola, 2006, Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine, J. Immunol., 176, 12, 10.4049/jimmunol.176.1.12

Miyamoto, 1999, Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy viaintercellular adhesion molecule-1 inhibition, Proc. Natl. Acad. Sci. U. S. A., 96, 10836, 10.1073/pnas.96.19.10836

Mizutani, 1996, Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy, J. Clin. Invest., 97, 2883, 10.1172/JCI118746

Mohammad, 2011, Novel role of mitochondrial matrix metalloproteinase-2 in the development of diabetic retinopathy, Invest. Ophthalmol. Vis. Sci., 52, 3832, 10.1167/iovs.10-6368

Mohammad, 2012, Diabetic retinopathy and signaling mechanism for activation of matrix metalloproteinase-9, J. Cell. Physiol., 227, 1052, 10.1002/jcp.22822

Mollica, 2007, Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities, Chem. Biol., 14, 431, 10.1016/j.chembiol.2007.03.007

Muranaka, 2006, Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood–retinal barrier in a streptozotocin-induced diabetic model, Invest. Ophthalmol. Vis. Sci., 47, 4547, 10.1167/iovs.05-1432

Ni, 2011, High glucose may decrease the innate immune through TLRs in cornea epithelium, Mol. Vis., 17, 3384

Nin, 2012, Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study, Eur. J. Endocrinol, 166, 325, 10.1530/EJE-11-0662

Nogueira-Machado, 2011, HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation, Expert Opin. Ther. Targets, 15, 1023, 10.1517/14728222.2011.575360

Ohnishi, 2011, HMGB1 inhibitor glycyrrhizin attenuates intracerebral hemorrhage-induced injury in rats, Neuropharmacology, 61, 975, 10.1016/j.neuropharm.2011.06.026

Oshitari, 2006, Effect of combined antisense oligonucleotides against high-glucose- and diabetes-induced overexpression of extracellular matrix components and increased vascular permeability, Diabetes, 55, 86, 10.2337/diabetes.55.01.06.db05-0186

Park, 2003, Activation of gene expression in human neutrophils by high mobility group box 1 protein, Am. J. Physiol. Cell. Physiol., 284, C870, 10.1152/ajpcell.00322.2002

Rogers, 1996, Occludin is a functional component of the tight junction, J. Cell. Sci., 109, 2287, 10.1242/jcs.109.9.2287

Roy, 2011, A long term siRNA strategy regulates fibronectin overexpression and improves vascular lesions in retinas of diabetic rats, Mol. Vis., 17, 3166

Roy, 2003, Downregulation of fibronectin overexpression reduces basement membrane thickening and vascular lesions in retinas of galactose-fed rats, Diabetes, 52, 1229, 10.2337/diabetes.52.5.1229

Sato, 1996, Therapeutic basis of glycyrrhizin on chronic hepatitis B, Antivir. Res., 30, 171, 10.1016/0166-3542(96)00942-4

Sitia, 2007, Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice, J. Leukoc. Biol., 81, 100, 10.1189/jlb.0306173

Schlueter, 2005, Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule, Am. J. Pathol., 166, 1259, 10.1016/S0002-9440(10)62344-9

Stitt, 1997, Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats, Am. J. Pathol., 150, 523

Tang, 2010, High-mobility group box 1 and cancer, Biochim. Biophys. Acta, 1799, 131, 10.1016/j.bbagrm.2009.11.014

Tavelin, 2003, A new principle for tight junction modulation based on occludin peptides, Mol. Pharmacol., 64, 1530, 10.1124/mol.64.6.1530

Treutiger, 2003, High mobility group 1 B-box mediates activation of human endothelium, J. Intern. Med., 254, 375, 10.1046/j.1365-2796.2003.01204.x

Ulloa, 2002, Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation, Proc. Natl. Acad. Sci. U. S. A., 99, 12351, 10.1073/pnas.192222999

van Beijnum, 2008, Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1), Angiogenesis, 11, 91, 10.1007/s10456-008-9093-5

Voll, 2008, High mobility group box 1 in the pathogenesis of inflammatory and autoimmune diseases, Isr. Med. Assoc. J., 10, 26

Volz, 2010, HMGB1: the missing link between diabetes mellitus and heart failure, Basic Res. Cardiol., 105, 805, 10.1007/s00395-010-0114-3

Wang, 1999, Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes, Surgery, 126, 389, 10.1016/S0039-6060(99)70182-0

Wang, 1999, HMG-1 as a late mediator of endotoxin lethality in mice, Science, 285, 248, 10.1126/science.285.5425.248

Yamada, 2007, HMGB1, a novel inflammatory cytokine, Clin. Chim. Acta, 375, 36, 10.1016/j.cca.2006.07.019

Yamashiro, 2003, Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood–retinal barrier breakdown, Am. J. Pathol., 163, 253, 10.1016/S0002-9440(10)63648-6

Yao, 2010, Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands, Diabetes, 59, 249, 10.2337/db09-0801

Yeh, 2001, Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappa B transcriptional activation and cytokine secretion, Diabetes, 50, 1495, 10.2337/diabetes.50.6.1495